[{"id":"e66ffbd6-de28-41ba-b035-1d5753011860","acronym":"","url":"https://clinicaltrials.gov/study/NCT05206071","created_at":"2022-01-25T15:53:37.949Z","updated_at":"2024-07-02T16:36:18.054Z","phase":"","brief_title":"Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05206071","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD19 • IFNG • IL6 • TNFA • CD22 • IL10","pipe":" | ","alterations":" CD20 positive • CD19 expression","tags":["CD19 • IFNG • IL6 • TNFA • CD22 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Senl_H19x22P"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-01-25"},{"id":"e84b6fb9-58df-4ebb-b205-149e85c08e31","acronym":"","url":"https://clinicaltrials.gov/study/NCT04626739","created_at":"2021-01-19T20:35:41.203Z","updated_at":"2024-07-02T16:36:38.698Z","phase":"Phase 1","brief_title":"CAR-T Cells in Treating Patients With Relapsed or Refractory NHL","source_id_and_acronym":"NCT04626739","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • CD19 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Senl_22 • Senl_H19x22P"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2020-11-13"}]